Jeremy Bender is the Chief Executive Officer and President of DAY ONE BIOPHARMACEUTICALS INC., a company focused on developing targeted therapies for patients with genetically defined cancers. With a robust background in the biopharmaceutical industry, Jeremy has been instrumental in steering DAY ONE towards its mission of bringing innovative treatments to patients in need. Before joining DAY ONE, Jeremy held several key leadership positions, including Chief Operating Officer at Principia Biopharma, where he played a pivotal role in the company's growth and eventual acquisition by Sanofi. At DAY ONE BIOPHARMACEUTICALS, Jeremy's strategic vision has been crucial in advancing the company's pipeline, particularly with the development of tovorafenib, a type II RAF inhibitor aimed at treating pediatric low-grade glioma. Under his leadership, DAY ONE has successfully navigated the complexities of clinical trials and regulatory pathways, culminating in the FDA's acceptance of the New Drug Application for tovorafenib in 2023. Jeremy's commitment to patient-centric innovation is evident in the company's collaborative approach with healthcare providers, researchers, and advocacy groups to ensure that new therapies are both effective and accessible. Jeremy's achievements extend beyond DAY ONE, as he has been recognized for his contributions to the biopharma sector through various industry awards and accolades. His expertise in operational strategy, drug development, and commercialization has not only propelled DAY ONE's success but has also positioned the company as a leader in the field of precision oncology. As CEO and President, Jeremy continues to drive DAY ONE's mission forward, emphasizing a culture of scientific excellence and compassionate care.